At QABY, we are driven by a singular mission: to transform the way Parkinson's disease (PD) and other synucleinopathies are diagnosed and treated. As a pioneering biotechnology startup based in Qatar, we are harnessing cutting-edge innovation to tackle one of the world's most pressing healthcare challenges.
QABY aims to revolutionize care for Parkinson's disease (PD) and other synucleinopathies, including multiple system atrophy (MSA) and dementia with Lewy bodies (DLB).
Our mission is to enable early, accurate diagnosis and develop therapies that address the root causes of these diseases, not just their symptoms.
Through scientific innovation, we strive to enhance patient outcomes and improve the quality of life for patients and their families.
QABY's innovative Seed Amplification Immunoassay (SAIA) and ELISA-based tests enable early and precise detection of Parkinson's disease, DLB, and MSA by identifying misfolded alpha-synuclein in biological samples such as CSF, blood and skin homogenates. These tools can improve diagnostic accuracy and support clinical trials for alpha-synuclein therapies and paving the way for targeted interventions.
QABY's innovative Seed Amplification Immunoassay (SAIA) and ELISA-based tests enable early and precise detection of Parkinson's disease, DLB, and MSA by identifying misfolded alpha-synuclein in biological samples such as CSF, blood and skin homogenates. These tools can improve diagnostic accuracy and support clinical trials for alpha-synuclein therapies and paving the way for targeted interventions.
QABY is at the forefront of developing nanobody-based therapies to target alpha-synuclein aggregates, the hallmark of PD and related disorders. Unlike traditional antibodies, nanobodies penetrate the blood-brain barrier and act intracellularly, offering a stable, specific, and potentially disease-modifying approach to halt or reverse neurodegeneration.
QABY is at the forefront of developing nanobody-based therapies to target alpha-synuclein aggregates, the hallmark of PD and related disorders. Unlike traditional antibodies, nanobodies penetrate the blood-brain barrier and act intracellularly, offering a stable, specific, and potentially disease-modifying approach to halt or reverse neurodegeneration.
QABY is striving to pioneer nanobody-based immuno-PET imaging to visualize alpha-synuclein aggregates in vivo, enabling early diagnosis, disease staging, and therapy monitoring in synucleinopathies.
QABY is striving to pioneer nanobody-based immuno-PET imaging to visualize alpha-synuclein aggregates in vivo, enabling early diagnosis, disease staging, and therapy monitoring in synucleinopathies.
Discover how our unique approach is revolutionizing the field of neurodegenerative disease research and treatment.
Our focus on novel technologies, such as Seed Amplification Immunoassays (SAIA) and nanobody therapies, places us at the forefront of synucleinopathy innovation.
From our base in Qatar, QABY is connecting regional innovation with global healthcare needs.
Every discovery is guided by our commitment to transforming lives and advancing care for those living with PD, DLB and MSA.
QABY is a pioneering biotechnology company founded by Dr. Omar El-Agnaf with a mission to revolutionize the diagnosis and treatment of PD and related synucleinopathies.
Established through a Share Redemption Agreement between HBKU R&D Corp QSTP-LLC and Dr. Omar El-Agnaf, QABY is rooted in the groundbreaking research and innovation at Hamad Bin Khalifa University (HBKU).
Pioneering Neurodegenerative Research
Dr. Omar El-Agnaf is a global leader in neurodegenerative disease research. With over 25 years of experience, he has made significant contributions to the field, advancing our understanding of the molecular mechanisms behind Parkinson's disease and paving the way for innovative diagnostic and therapeutic solutions.
As the former Executive Director of the Qatar Biomedical Research Institute (QBRI), Dr. El-Agnaf led the institute to international acclaim, securing substantial research funding and establishing impactful collaborations with biotech and pharmaceutical companies.
At QABY, we're at the forefront of neurodegenerative disease research, focusing on innovative approaches to diagnose and treat conditions like Parkinson's disease. Our groundbreaking work in Seed Amplification Immunoassay (SAIA) and nanobody-based therapies is paving the way for earlier detection and more effective treatments, potentially transforming the lives of millions affected by these debilitating conditions.
We're excited to hear from you and discuss how QABY can revolutionize neurodegenerative disease care.